×
About 5 results

EMA Recommends Extension of Therapeutic Indications for Vandetanib
https://www.esmo.org/oncology-news/archive/ema-recommends-extension-of-therapeutic-indications-for-vandetanib

Nov 14th, 2016 - On 10 November 2016, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product vandetanib (Caprelsa). The marketing authorisation holder for this medicinal product is Genzyme Europe BV. The CHMP adopted an extension to the existing indication...

Pfizer ends deal with Pain Therapeutics to develop Durect's pain drug
https://www.reuters.com/article/us-durect-pain-therapeutic-drugs/pfizer-ends-deal-with-pain-therapeutics-to-develop-durects-pain-drug-idUSKBN0IG1HE20141027

Oct 27th, 2014 - A man walks past Pfizer's world headquarters in New York April 28, 2014. REUTERS/Andrew Kelly (Reuters) - Pfizer Inc ended an agreement with Pain Therapeutics Inc to develop and market Durect Corp’s pain drug, Remoxy, sending the stocks of the two smaller drugmakers plummeting. Durect’s shares fell as much as 46 percent in early trading on Monday, while Pain Therapeutics stock slumped 61 percen...